Obchod FibroGen, Inc - FGEN CFD
Pridať medzi obľúbené- Zhrnutie
- Historické dáta
- Udalosti
- Výkaz ziskov a strát
- Súvahový list
- Peňažný tok
- Vlastníctvo
Podmienky obchodovania
| Rozpätie | 0.18 | ||||||||
|
Nočný poplatok dlhej pozície
Long position overnight fee
Prejsť na platformu | -0.025457% | ||||||||
|
Nočný poplatok krátkej pozície
Short position overnight fee
Prejsť na platformu | 0.003235% | ||||||||
| Nočný poplatok | 21:00 (UTC) | ||||||||
| Minimálne množstvo na obchodovanie | 1 | ||||||||
| Mena | USD | ||||||||
| Marža | 20% | ||||||||
| Burza cenných papierov | United States of America | ||||||||
| Provízia pri predaji | 0% |
*Information provided by Capital.com
FibroGen Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Kľúčové štatistiky
| Predchádzajúce Zavrieť* | 17.02 |
| Otvoriť* | 16.74 |
| 1-ročná zmena* | 60.19% |
| Denný rozsah* | 16.5 - 17.85 |
| Rozsah 52 týždňov | 8.67-25.69 |
| Priemerný objem (10 dní) | 1.08M |
| Priemerný objem (3 mesiace) | 19.19M |
| Trhová kapitalizácia | 1.67B |
| Pomer P/E | -100.00K |
| Zdieľa mimoriadne | 97.58M |
| Výnosy | 116.07M |
| EPS | -3.27 |
| Dividenda (udalosť %) | N/A |
| Beta | 0.79 |
| Ďalší dátum zárobku | Aug 7, 2023 |
Všetky údaje poskytuje spoločnosť Refinitiv, okrem údajov označených hviezdičkou, čo sú *údaje poskytnuté Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zatvorenie | Change | Change (%) | Otvorenie | High | Low |
|---|---|---|---|---|---|---|
| Jun 8, 2023 | 17.63 | 1.31 | 8.03% | 16.32 | 17.85 | 16.28 |
| Jun 7, 2023 | 17.02 | -0.97 | -5.39% | 17.99 | 18.42 | 16.35 |
| Jun 6, 2023 | 18.54 | -0.46 | -2.42% | 19.00 | 19.14 | 18.53 |
| Jun 5, 2023 | 19.05 | 1.83 | 10.63% | 17.22 | 19.43 | 17.22 |
| Jun 2, 2023 | 17.79 | -0.94 | -5.02% | 18.73 | 19.05 | 17.34 |
| Jun 1, 2023 | 17.18 | 0.22 | 1.30% | 16.96 | 17.59 | 16.70 |
| May 31, 2023 | 17.16 | 0.15 | 0.88% | 17.01 | 17.61 | 16.72 |
| May 30, 2023 | 17.04 | 0.47 | 2.84% | 16.57 | 17.33 | 16.46 |
| May 26, 2023 | 16.65 | 0.03 | 0.18% | 16.62 | 16.80 | 16.33 |
| May 25, 2023 | 16.82 | 0.16 | 0.96% | 16.66 | 16.91 | 16.44 |
| May 24, 2023 | 16.90 | -0.05 | -0.29% | 16.95 | 17.33 | 16.51 |
| May 23, 2023 | 17.27 | 0.06 | 0.35% | 17.21 | 18.03 | 16.99 |
| May 22, 2023 | 17.16 | -0.14 | -0.81% | 17.30 | 18.02 | 16.96 |
| May 19, 2023 | 17.49 | -0.07 | -0.40% | 17.56 | 18.07 | 17.20 |
| May 18, 2023 | 17.53 | 0.01 | 0.06% | 17.52 | 17.89 | 17.29 |
| May 17, 2023 | 17.77 | 0.80 | 4.71% | 16.97 | 17.86 | 16.92 |
| May 16, 2023 | 17.40 | 0.25 | 1.46% | 17.15 | 17.51 | 17.08 |
| May 15, 2023 | 17.58 | 0.46 | 2.69% | 17.12 | 17.91 | 17.03 |
| May 12, 2023 | 17.31 | -0.11 | -0.63% | 17.42 | 17.66 | 17.09 |
| May 11, 2023 | 17.48 | -0.12 | -0.68% | 17.60 | 18.00 | 17.38 |
FibroGen, Inc Events
| Čas (UTC) (UTC) | Krajina | Udalosť |
|---|---|---|
| Monday, June 12, 2023 | ||
| Čas (UTC) (UTC) 18:20 | Krajina US
| Udalosť FibroGen Inc at Goldman Sachs Healthcare Conference FibroGen Inc at Goldman Sachs Healthcare ConferenceForecast -Previous - |
| Friday, June 16, 2023 | ||
| Čas (UTC) (UTC) 15:00 | Krajina US
| Udalosť FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Čas (UTC) (UTC) 10:59 | Krajina US
| Udalosť Q2 2023 FibroGen Inc Earnings Release Q2 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Čas (UTC) (UTC) 10:59 | Krajina US
| Udalosť Q3 2023 FibroGen Inc Earnings Release Q3 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
- Výročný
- Štvrťročne
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Celkové príjmy | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Výnosy | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Celkové prevádzkové náklady | 441.759 | 523.839 | 368.199 | 345.891 | 299.651 |
| Predaj/Všeobecné/Správca. Náklady, Celkom | 127.474 | 120.557 | 97.238 | 126.557 | 63.812 |
| Výskum a vývoj | 296.791 | 387.043 | 252.924 | 209.265 | 235.839 |
| Prevádzkový príjem | -301.025 | -288.53 | -191.88 | -89.314 | -86.693 |
| Úrokový príjem (výdavky), čistý neprevádzkový | 6.156 | -2.153 | 3.151 | 12.672 | 0.577 |
| Čistý príjem pred zdanením | -294.869 | -290.683 | -188.729 | -76.642 | -86.116 |
| Čistý príjem po zdanení | -295.227 | -291.03 | -189.089 | -76.97 | -86.42 |
| Čistý príjem pred extra. Položky | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Čistý príjem | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Príjem k dispozícii bežnému Extra. Položky | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Príjem k dispozícii bežnému vr. Extra. Položky | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Zriedený čistý príjem | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Zriedený vážený priemer akcií | 93.582 | 92.349 | 89.854 | 86.633 | 84.062 |
| Zriedený EPS s výnimkou mimoriadnych položiek | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Zriedený normalizovaný EPS | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Celkom mimoriadne položky | |||||
| Náklady na výnosy, celkom | 20.28 | 12.871 | 8.869 | 1.147 | |
| Hrubý zisk | 120.454 | 222.438 | 167.45 | 255.43 | |
| Depreciation / Amortization | 0.587 | 4.639 | 10.369 | 10.307 | |
| Other Operating Expenses, Total | -3.373 | -1.271 | -1.201 | -1.385 | |
| Equity In Affiliates | 1.573 | 1.007 | -0.202 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Celkové príjmy | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Výnosy | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Náklady na výnosy, celkom | 3.491 | 4.925 | 4.308 | 6.809 | 4.238 |
| Hrubý zisk | 32.67 | 29.442 | 11.427 | 22.997 | 56.589 |
| Celkové prevádzkové náklady | 112.252 | 100.519 | 109.392 | 108.03 | 123.82 |
| Predaj/Všeobecné/Správca. Náklady, Celkom | 34.275 | 33.966 | 29.902 | 30.258 | 30.564 |
| Výskum a vývoj | 74.486 | 61.628 | 75.182 | 70.963 | 89.018 |
| Other Operating Expenses, Total | |||||
| Prevádzkový príjem | -76.091 | -66.152 | -93.657 | -78.224 | -62.993 |
| Úrokový príjem (výdavky), čistý neprevádzkový | -1.336 | -0.195 | 1.714 | 5.058 | -0.419 |
| Čistý príjem pred zdanením | -77.427 | -66.347 | -91.943 | -73.166 | -63.412 |
| Čistý príjem po zdanení | -77.501 | -66.455 | -92.057 | -73.189 | -63.525 |
| Equity In Affiliates | 0.796 | 0.28 | 0.407 | 0.565 | 0.32 |
| Čistý príjem pred extra. Položky | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Čistý príjem | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Príjem k dispozícii bežnému Extra. Položky | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Príjem k dispozícii bežnému vr. Extra. Položky | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Zriedený čistý príjem | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Zriedený vážený priemer akcií | 94.691 | 94.035 | 93.767 | 93.475 | 93.043 |
| Zriedený EPS s výnimkou mimoriadnych položiek | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Zriedený normalizovaný EPS | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
- Výročný
- Štvrťročne
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Celkové aktíva | 492.826 | 474.059 | 755.11 | 702.49 | 690.015 |
| Hotovosť a krátkodobé investície | 422.008 | 405.19 | 686.537 | 533.757 | 621.402 |
| Cash | 135.819 | 111.422 | 88.046 | 40.715 | 38.783 |
| Hotovosť a ekvivalenty | 19.881 | 59.801 | 590.347 | 85.551 | 50.475 |
| Krátkodobé investície | 266.308 | 233.967 | 8.144 | 407.491 | 532.144 |
| Pohľadávky celkom, netto | 16.299 | 25.401 | 41.883 | 153.665 | 63.684 |
| Accounts Receivable - Trade, Net | 28.387 | 36.331 | 46.01 | 158.51 | 16.474 |
| Prepaid Expenses | 9.73 | 7.383 | 8.353 | 6.464 | 4.929 |
| Total Assets | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Property/Plant/Equipment, Total - Net | 100.933 | 120.15 | 65.296 | 84.276 | 127.198 |
| Property/Plant/Equipment, Total - Gross | 253.644 | 252.362 | 199.305 | 195.752 | 192.397 |
| Accumulated Depreciation, Total | -152.711 | -132.212 | -134.009 | -111.476 | -65.199 |
| Long Term Investments | 9.409 | 171.621 | 2.972 | 61.118 | 55.82 |
| Other Long Term Assets, Total | 6.919 | 7.991 | 3.462 | 9.513 | 7.565 |
| Total Current Liabilities | 273.562 | 225.497 | 163.187 | 102.745 | 89.033 |
| Accounts Payable | 30.758 | 26.097 | 24.789 | 6.088 | 9.139 |
| Accrued Expenses | 229.639 | 180.356 | 104.384 | 83.816 | 66.123 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 13.129 | 19.033 | 21.684 | 0.49 | 13.771 |
| Total Liabilities | 631.534 | 564.675 | 404.662 | 341.262 | 371.399 |
| Total Long Term Debt | 17.054 | 17.616 | 44.088 | 55.531 | 113.955 |
| Long Term Debt | 16.917 | 17.613 | 18.697 | 16.78 | 16.798 |
| Capital Lease Obligations | 0.137 | 0.003 | 25.391 | 38.751 | 97.157 |
| Minority Interest | 19.967 | 19.967 | 19.271 | 19.271 | 19.271 |
| Other Liabilities, Total | 320.951 | 292.403 | 169.441 | 163.715 | 149.14 |
| Total Equity | -21.447 | 209.146 | 422.178 | 516.135 | 509.199 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.942 | 0.929 | 0.914 | 0.877 | 0.854 |
| Additional Paid-In Capital | 1541.02 | 1476.41 | 1399.77 | 1300.72 | 1226.45 |
| Retained Earnings (Accumulated Deficit) | -1557.69 | -1264.03 | -974.011 | -784.72 | -715.827 |
| Other Equity, Total | -5.72 | -4.163 | -4.499 | -0.747 | -2.281 |
| Total Liabilities & Shareholders’ Equity | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Total Common Shares Outstanding | 94.1661 | 92.881 | 91.441 | 87.657 | 85.432 |
| Total Inventory | 40.436 | 31.015 | 16.53 | 6.887 | |
| Other Current Assets, Total | 4.353 | 5.07 | 1.807 | 1.717 | |
| Current Port. of LT Debt/Capital Leases | 0.036 | 0.011 | 12.33 | 12.351 | |
| Deferred Income Tax | 9.192 | 8.675 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Celkové aktíva | 430.549 | 492.826 | 474.224 | 520.643 | 524.415 |
| Hotovosť a krátkodobé investície | 355.949 | 422.008 | 408.52 | 438.133 | 428.075 |
| Cash | 145.81 | 135.819 | 104.509 | 128.152 | 165.436 |
| Hotovosť a ekvivalenty | 42.74 | 19.881 | 51.451 | 39.606 | 20.46 |
| Krátkodobé investície | 167.399 | 266.308 | 252.56 | 270.375 | 242.179 |
| Pohľadávky celkom, netto | 17.654 | 16.299 | 15.328 | 33.573 | 43.883 |
| Accounts Receivable - Trade, Net | 29.217 | 28.387 | 29.665 | 60.352 | 82.638 |
| Total Inventory | 42.456 | 40.436 | 39.95 | 40.899 | 43.067 |
| Prepaid Expenses | 14.49 | 9.73 | 10.426 | 8.038 | 9.39 |
| Other Current Assets, Total | 4.353 | ||||
| Total Assets | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Property/Plant/Equipment, Total - Net | 95.367 | 100.933 | 105.19 | 109.159 | 114.871 |
| Property/Plant/Equipment, Total - Gross | 253.644 | ||||
| Accumulated Depreciation, Total | -152.711 | ||||
| Long Term Investments | 5.884 | 9.409 | 22.411 | 50.414 | 97.643 |
| Other Long Term Assets, Total | 6.744 | 6.919 | 7.012 | 6.573 | 9.005 |
| Total Current Liabilities | 254.746 | 273.562 | 251.994 | 240.34 | 255.374 |
| Accounts Payable | 71.282 | 30.758 | 19.323 | 29.36 | 36.353 |
| Accrued Expenses | 166.969 | 229.639 | 224.577 | 202.681 | 211.518 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.036 | ||||
| Other Current Liabilities, Total | 16.495 | 13.129 | 8.094 | 8.299 | 7.503 |
| Total Liabilities | 587.396 | 631.534 | 582.531 | 583.009 | 587.886 |
| Total Long Term Debt | 17.276 | 17.054 | 15.422 | 16.439 | 17.374 |
| Long Term Debt | 17.276 | 16.917 | 15.422 | 16.439 | 17.374 |
| Capital Lease Obligations | 0.137 | ||||
| Deferred Income Tax | |||||
| Minority Interest | 19.967 | 19.967 | 19.967 | 19.967 | 19.967 |
| Other Liabilities, Total | 295.407 | 320.951 | 295.148 | 306.263 | 295.171 |
| Total Equity | -48.852 | -21.447 | 26.306 | 103.78 | 158.048 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.966 | 0.942 | 0.939 | 0.937 | 0.933 |
| Additional Paid-In Capital | 1589.15 | 1541.02 | 1524.23 | 1509.64 | 1490.86 |
| Retained Earnings (Accumulated Deficit) | -1634.39 | -1557.69 | -1491.51 | -1399.86 | -1327.24 |
| Other Equity, Total | -4.57 | -5.72 | -7.346 | -6.93 | -6.505 |
| Total Liabilities & Shareholders’ Equity | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Total Common Shares Outstanding | 96.623 | 94.1661 | 93.936 | 93.733 | 93.289 |
- Výročný
- Štvrťročne
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Čistý príjem/Počiatočná čiara | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Hotovosť z prevádzkovej činnosti | -145.933 | -82.232 | 81.602 | -78.705 | -76.144 |
| Hotovosť z prevádzkovej činnosti | 10.604 | 14.809 | 22.047 | 21.454 | 6.562 |
| Bezhotovostné položky | 66.687 | 132.899 | 74.216 | 62.47 | 52.112 |
| Úroky zaplatené v hotovosti | 0.104 | 0.094 | 0.135 | 0.174 | 0.218 |
| Zmeny pracovného kapitálu | 70.43 | 60.083 | 174.63 | -85.659 | -48.398 |
| Peniaze z investičných činností | 89.116 | -426.972 | 452.487 | 120.018 | -522.123 |
| Kapitálové výdavky | -38.741 | -30.186 | -3.994 | -5.762 | -8.02 |
| Ostatné investičné položky peňažných tokov, celkom | 127.857 | -396.786 | 456.481 | 125.78 | -514.103 |
| Hotovosť z finančných činností | 46.776 | -0.563 | 13.343 | -4.3 | 13.875 |
| Financovanie položiek peňažných tokov | -6.62 | -7.372 | -11.463 | -12.75 | -15.612 |
| Vydanie (vyradenie) zásob, netto | 53.934 | 12.701 | 37.829 | 20.778 | 29.847 |
| Vydanie (vyradenie) dlhu, netto | -0.538 | -5.892 | -13.023 | -12.328 | -0.36 |
| Devízové efekty | -5.482 | 2.597 | 4.695 | -0.005 | -0.008 |
| Čistá zmena v hotovosti | -15.523 | -507.17 | 552.127 | 37.008 | -584.4 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -76.705 | -293.654 | -227.479 | -135.829 | -63.205 |
| Cash From Operating Activities | -101.591 | -145.933 | -93.42 | -41.54 | -8.476 |
| Cash From Operating Activities | 2.965 | 10.604 | 7.914 | 5.235 | 2.584 |
| Non-Cash Items | 18.148 | 66.687 | 49.928 | 34.441 | 17.77 |
| Changes in Working Capital | -45.999 | 70.43 | 76.217 | 54.613 | 34.375 |
| Cash From Investing Activities | 103.482 | 89.116 | 88.023 | 43.24 | 25.935 |
| Capital Expenditures | -0.591 | -38.741 | -38.408 | -37.543 | -36.638 |
| Other Investing Cash Flow Items, Total | 104.073 | 127.857 | 126.431 | 80.783 | 62.573 |
| Cash From Financing Activities | 31.485 | 46.776 | -1.898 | -0.806 | -2.893 |
| Financing Cash Flow Items | 0 | -6.62 | -4.562 | -3.361 | -2.974 |
| Issuance (Retirement) of Stock, Net | 31.657 | 53.934 | 2.989 | 2.779 | 0.183 |
| Issuance (Retirement) of Debt, Net | -0.172 | -0.538 | -0.325 | -0.224 | -0.102 |
| Foreign Exchange Effects | -0.526 | -5.482 | -7.968 | -4.359 | 0.107 |
| Net Change in Cash | 32.85 | -15.523 | -15.263 | -3.465 | 14.673 |
| Meno investora | Typ investora | Percento vynikajúce | Držané akcie | Zmena akcií | Dátum držby | Hodnotenie obratu |
|---|---|---|---|---|---|---|
| PRIMECAP Management Company | Investment Advisor | 14.4767 | 14126697 | 231619 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.0286 | 8810326 | -613439 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2737 | 6122003 | 89685 | 2023-03-31 | LOW |
| Astellas Pharma Inc | Corporation | 5.0915 | 4968367 | 0 | 2023-01-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1772 | 4076167 | -188810 | 2023-03-31 | LOW |
| Point72 Asset Management, L.P. | Hedge Fund | 3.5113 | 3426427 | -1355218 | 2023-03-31 | HIGH |
| First Trust Advisors L.P. | Investment Advisor | 2.7884 | 2720975 | -254678 | 2023-03-31 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 2.7027 | 2637384 | 1262173 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 2.3693 | 2312000 | -1552000 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7703 | 1727545 | 70450 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.7676 | 1724909 | 512435 | 2023-03-31 | HIGH |
| Schroder Investment Management North America Inc. | Investment Advisor | 1.5138 | 1477161 | -246616 | 2023-03-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 1.3847 | 1351230 | 1351230 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3779 | 1344583 | 1344583 | 2023-03-31 | HIGH |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.1877 | 1159027 | -348288 | 2023-03-31 | MED |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.1157 | 1088768 | 593915 | 2023-03-31 | LOW |
| Eventide Asset Management, LLC | Investment Advisor | 0.9838 | 960000 | 960000 | 2023-03-31 | MED |
| Nuveen LLC | Pension Fund | 0.9185 | 896293 | 328958 | 2023-03-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 0.8711 | 850000 | -1800000 | 2023-03-31 | MED |
| Eagle Asset Management, Inc. | Investment Advisor/Hedge Fund | 0.8488 | 828307 | -74825 | 2023-03-31 | LOW |
Prečo si vybrať Capital.com? Naše čísla hovoria samy za seba.
Capital.com Group535K+
Obchodníci
87K+
Aktívni klienti za mesia
$113M+
Mesačný objem investícií
$64M+
Výbery každý mesiac
Obchodná kalkulačka
Vypočítajte si svoj hypotetický zisk a stratu, ak ste otvorili obchod s CFD v určitý deň (vyberte dátum) a uzavreli v iný dátum (vyberte dátum).
Obchodná provízia
0
- 1:1
Leverage (pákový efekt)
1:1
- 20
- 100
- 500
- 1000
- 10000
Investície
Veľkosť obchodu (pákový efekt x investície):
Otvorenie
Zatvorenie
Krátke Dlhé
FibroGen, Inc Company profile
O spoločnosti FibroGen, Inc
FibroGen, Inc. je biofarmaceutická spoločnosť. Spoločnosť sa zaoberá objavovaním, vývojom a komercializáciou prvotriednych terapeutických prípravkov. Spoločnosť využíva svoje schopnosti v oblasti biológie faktora indukovaného hypoxiou (HIF), enzymológie 2-oxoglutarátu a biológie rastového faktora spojivového tkaniva (CTGF) na vývoj liekov na liečbu anémie, fibrotických ochorení a rakoviny. Produkt spoločnosti Roxadustat je perorálny malomolekulový inhibítor aktivity HIF-prolylhydroxylázy (HIF-PH) na liečbu anémie spôsobenej chronickým ochorením obličiek (CKD). Roxadustat vyvíja aj na liečbu anémie spojenej s myelodysplastickými syndrómami (MDS). Spoločnosť tiež vyvíja Roxadustat na liečbu anémie vyvolanej chemoterapiou (CIA). Pamrevlumab, ľudskú monoklonálnu protilátku proti CTGF na liečbu idiopatickej pľúcnej fibrózy (IPF), lokálne pokročilého neresekovateľného karcinómu pankreasu (LAPC) a Duchenneovej svalovej dystrofie (DMD).
| Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
Výkaz ziskov a strát
- Annual
- Quarterly
Ľudia tiež sledujú
Stále hľadáte brokera, ktorému sa dá veriť?
Pridajte sa k 535 000 obchodníkom na celom svete, ktorí sa rozhodli obchodovať s Capital.com